Related Experiment Video
Updated: Sep 5, 2026
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Efficacy and safety of bispecific antibodies versus other antitumor therapies in solid tumors: a systematic review
Yici Yan1, Weidong Gao1, Zhenzheng Zhu1
1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Background:
Bispecific antibodies (BsAbs) have emerged as a promising strategy for solid tumor treatment, yet their comparative efficacy and safety versus other antitumor therapies remain unclear.
Materials And Methods:
Literature was systematically searched in PubMed, Embase, Cochrane Library, and Scopus from inception up to August 2026. American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and clinicaltrials.gov were also checked. Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and adverse events (AEs) were used to assess efficacy and safety. Publication bias was assessed using funnel plots. Heterogeneity was evaluated using subgroup, meta-regression and sensitivity analyses. The protocol was preregistered in the International Prospective Register of Systematic Reviews (CRD420261359397).
Results:
A total of 9 eligible studies involving 3,505 patients were included. Compared with other antitumor therapies, BsAbs demonstrated significant improvements in PFS (hazard ratio [HR]: 0.76, 95% confidence interval [CI]: 0.61-0.94, p=0.011) and OS (HR: 0.78, 95% CI: 0.63-0.95, p=0.016). ORR showed a borderline effect (Risk Ratio [RR]: 1.20, 95% CI: 1.00-1.44, p=0.046). Subgroup analyses suggested potential benefits in selected populations, particularly among patients treated with T-cell engaging BsAbs or tumor microenvironment/angiogenesis-modulating BsAbs, patients aged <65 years, and patients with non-small cell lung cancer (NSCLC). Regarding safety, renal and vascular toxicities, including proteinuria, peripheral edema, and hypertension, as well as immune-related toxicities such as cytokine release syndrome and rash, were more frequently observed in the BsAb group. Other increased adverse events included anemia, pain in extremity, decreased appetite, and vomiting.
Conclusion:
BsAb-based regimens significantly improve PFS and OS compared with non-BsAb antitumor therapies in patients with solid tumors. Although the overall AE profile appeared manageable, renal and vascular toxicities and immune-related/inflammatory toxicities warrant particular attention.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261359397.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Drug Products: Biologics, Biosimilars and Interchangeables